Listando por materia "Terapia PEG-IFN"

Mostrando ítems 1-1 de 1

Boceprevir plus pegylated interferon/ribavirin to re-treat hepatitis C virus genotype 1 in HIV–HCV co-infected patients: final results of the Spanish BOC HIV–HCV Study

Laguno, M.; Von Wichmann, M. A.; Van den Eynde, E.; Navarro, J.; Cifuentes, Carmen; Murillas, J.; Veloso, S.; Martínez-Rebollar, M.; Guardiola, J.M.; Jou, A.; Gómez-Sirvent, J.L.; Cervantes, M.; Pineda, J.A.; López-Calvo, S.; Carrero, Ana; Montes, M.L.; Deig, E.; Tapiz, A.; Ruiz-Mesa, J.D.; Cruceta, A.; de Lazzari, E.; Mallolas, Josep (International Journal of Infectious Diseases, 2016-12)

Introduction: Boceprevir (BOC) was one of the first oral inhibitors of hepatitis C virus (HCV) NS3 protease to be developed. This study assessed the safety and efficacy of BOC + pegylated interferon-α ...